To assess the potential clinical significance of our in vitro results, we tested PDGFRα expression in biopsies obtained from 9 melanoma patients treated with BRAF-I or with the novel combination of BRAF-I and MEK inhibitor (MEK-I) [21]. This evidence concerns the gene BRAF and melanoma.